Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Market Cap
$1.49B
Net Profit Margin
12.02%
TTM Avg
-7.78%
3Y Avg
-15.24%
5Y Avg
-11964.64%
Market Cap
$1.46B
Net Profit Margin
6.59%
TTM Avg
2.75%
3Y Avg
2.46%
5Y Avg
3.07%
Market Cap
$1.53B
Net Profit Margin
80.56%
TTM Avg
35.15%
3Y Avg
48.19%
5Y Avg
54.54%
Market Cap
$1.52B
Net Profit Margin
-16.75%
TTM Avg
-1.75%
3Y Avg
-3.69%
5Y Avg
-6.61%
Market Cap
$1.45B
Net Profit Margin
-667.95%
TTM Avg
15.59%
3Y Avg
7.79%
5Y Avg
7.79%
Market Cap
$1.42B
Net Profit Margin
82.37%
TTM Avg
-82.37%
3Y Avg
-592.43%
5Y Avg
-414.63%
Market Cap
$1.40B
Net Profit Margin
-10773.46%
TTM Avg
416506.27%
3Y Avg
203244.58%
5Y Avg
135206.06%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.49B | 0.00% | 0.00% | 0.00% | 0.00% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 12.02% | -7.78% | -15.24% | -11964.64% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 6.59% | 2.75% | 2.46% | 3.07% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.53B | 80.56% | 35.15% | 48.19% | 54.54% |
| Certara, Inc. (CERT)vs › | $1.52B | -16.75% | -1.75% | -3.69% | -6.61% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | -667.95% | 15.59% | 7.79% | 7.79% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 82.37% | -82.37% | -592.43% | -414.63% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -10773.46% | 416506.27% | 203244.58% | 135206.06% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.35B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
